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ABSTRACT
Small interfering RNA (siRNA)-based drugs require
chemical modifications or formulation to promote
stability, minimize innate immunity, and enable de-
livery to target tissues. Partially modified siRNAs
(up to 70% of the nucleotides) provide significant
stabilization in vitro and are commercially available;
thus are commonly used to evaluate efficacy of bio-
conjugates for in vivo delivery. In contrast, most
clinically-advanced non-formulated compounds, us-
ing conjugation as a delivery strategy, are fully chem-
ically modified (100% of nucleotides). Here, we com-
pare partially and fully chemically modified siRNAs
in conjugate mediated delivery. We show that fully
modified siRNAs are retained at 100x greater lev-
els in various tissues, independently of the nature of
the conjugate or siRNA sequence, and support pro-
ductive mRNA silencing. Thus, fully chemically stabi-
lized siRNAs may provide a better platform to identify
novel moieties (peptides, aptamers, small molecules)
for targeted RNAi delivery.
INTRODUCTION
A variety of chemical modification patterns have been ex-
plored to improve siRNA stability (1), ranging from the
simple introduction of a dTdT overhang to highly compli-
cated patterns that remove the chemical nature of RNA (2).
Commonly used, commercially available scaffolds include
modification of every other nucleotide (3) or all pyrimidines
in a given sequence (4). These ‘conventional’ modification
patterns substantially enhance siRNA stability in vitro (5)
and block innate immune activation in vivo (6).
Partially modified siRNAs have been extensively used to
study the impact of conjugates on siRNA distribution and
in vivo efficacy. A wide range of conjugate modalities have
been tested: steroids (7), lipids (8), folate (9), vitamins (10),
aptamers (11) and antibodies (12) all demonstrating only
marginal efficacy. All of these conjugates were evaluated in
the context of naked or partially modified siRNA,miRNAs
and antisense oligonucleotides.
A recent breakthrough in conjugate-mediated delivery
was the development of the triple N-acetylgalactosamine
(GalNAc) conjugated siRNA (13), which drives efficient,
receptor-mediated uptake into hepatocytes. The GalNAc-
conjugated siRNAs were fully modified using an advanced
version of an alternating 2′-fluoro, 2′-O-methyl pattern first
described in 2005 (3). Additionally, in the context of single
stranded RISC entering oligonucleotides, chemical stabi-
lization was shown to be absolutely essential for in vivo effi-
cacy (14,15). Recently, fine-tuning of the chemical stabiliza-
tion pattern, including increases in the 2′-O-methyl content,
incorporation of additional phosphorothioates (14) and 5′
phosphate stabilization (16–19) have been shown to even
further enhance long-term efficacy of conjugated siRNAs.
Here, we systematically compare the distribution, tissue
accumulation, and efficacy of partially and fully modified
siRNA scaffolds and show that full chemical stabilization
of siRNA is preferred for in vivo applications, independently
of the siRNA sequence or the nature of the conjugate used.
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MATERIALS AND METHODS
Oligonucleotide synthesis, deprotection and purification
Oligonucleotideswere synthesized using standard andmod-
ified (2′-fluoro, 2′-O-methyl) phosphoramidite, solid-phase
synthesis conditions using aMerMade 12 (BioAutomation,
Irving, TX, USA) and Expedite DNA/RNA synthesizer
(ABI 8909). Unconjugated oligonucleotide strands were
grown on controlled pore glass functionalized with a long-
chain alkyl amine and Unylinker® terminus (Chemgenes,
#N-4000-10) and cholesterol-conjugated oligonucleotides
were synthesized on modified solid support (Chemgenes,
# N-9166-05). Oligonucleotides were removed from CPG,
deprotected, and purified by HPLC as described previ-
ously (20). Purified oligonucleotides were passed over a Hi-
Trap cation exchange column to exchange the counter-ion
with sodium. Oligonucleotides identity were confirmed by
HPLC–mass spectrometry.
In vitro RISC loading and cleavage assay
S100 cell extract from ago2−/− +Ago2 MEF cells were in-
cubated with 50 nM chemically modified or unmodified let-
7a siRNA for 30 min at 37◦C. After 30 min, 100 nM of
32P capped labeled RNA was incubated at 23◦C for 10 min
to measure RISC concentration. After 10 min, temperature
was shifted to 37◦C (multi-turnover condition). Cell extract,
RNA labeling, and cleavage assay were performed as previ-
ously described by Salomon et al. (21).
Cell culture (HeLa and CTB cells)
HeLa cells (ATCC, #CCL-2) were maintained in DMEM
(Cellgro, #10–013CV) supplemented with 10% fetal
bovine serum (FBS) (Gibco, #26140) and 100 U/ml
penicillin/streptomycin (Invitrogen, #15140) and grown
at 37◦C and 5% CO2. Cells were split every 2–5 days, and
discarded after fifteen passages. Primary cytotrophoblast
cells (CTB) from human placenta were provided by Dr. S
Ananth Karumanchi. CTBs were maintained in Medium
119 (Gibco, #11043) supplemented with 10% FBS (Gibco,
#26140) and 100U/ml penicillin/streptomycin (Invitrogen,
#15140) at 37◦C and 5% CO2.
Preparation of primary neurons
Mouse primary cortical neurons were prepared as previ-
ously described (22). In brief, pregnant C57BL6 females
were anesthetized with Avertin (Sigma, #T48402), followed
by cervical dislocation. Brains of E15.5 day embryos were
removed, and meninges were carefully detached. Cortices
were isolated and transferred into a 1.5-ml tube with pre-
warmed papain solution for 25min at 37◦C, 5%CO2, to dis-
solve tissue. Cortices were dissociated by repeated pipetting
and plated on poly-L-lysine coated plates. Anti-mitotics,
0.484 l/ml of UTP Na3 (Sigma, #U6625) and 0.2402
l/ml of FdUMP (Sigma, #F3503), were added to neuronal
cultures to prevent growth of non-neuronal cells. Protocols
for oligonucleotide treatment have been described in detail
in Alterman et al. bioprotocols(22).
Hepatocyte cell culture
Human primary hepatocytes (Gibco, #HMCPUS) were
thawed and plated in Cryopreserved Hepatocytes Recov-
ery Medium (Gibco, #CM7000), consisting of Williams E
Medium (Gibco, #A12176-01) supplemented with 5% fetal
bovine serum, 1 M dexamethasone in DMSO, 100 U/ml
penicillin and streptomycin, 4 g/ml human recombinant
insulin, 2 mM GlutaMAX and 15 mM HEPES pH 7.4.
Plated hepatocytes were allowed to recover for 6 h at 37◦C
and 5% CO2 and subsequently maintained in Williams E
Medium supplemented with the Hepatocyte Maintenance
Supplement Pack (Gibco, #CM4000), containing 0.1 M
dexamethasone in DMSO, 50 U/ml penicillin and strepto-
mycin, 6.25 g/ml human recombinant insulin, 6.25 g/ml
human transferrin, 6.25 g/ml selenous acid, 6.25 g/ml
bovine serum albumin, 6.25g/ml linoleic acid, 2 mMGlu-
taMAX,15 mM HEPES pH 7.4 and 5 mM CaCl2.
Passive uptake of oligonucleotides (HeLa and CTB cells)
Cells were plated in DMEM containing 6% FBS at 10 000
cells per well in 96-well tissue culture plates. CTB cells were
plated in Medium 199 containing 6% FBS at 25 000 cells
per well in 96-well plates. Hydrophobically modified siRNA
(hsiRNA) was diluted in OptiMEM (Gibco, #31985-088),
and added to cells resulting in 3% FBS final. Cells were
incubated for 72 h at 37◦C and 5% CO2. Cells were lysed
andmRNAquantificationwas performed using theQuanti-
Gene 2.0 assay kit (Affymetrix).
Passive uptake of oligonucleotides (hepatocytes)
Cells were plated inWilliams EMedium supplemented with
the Hepatocyte Maintenance Supplement Pack (Gibco,
#CM4000) at 25 000 cells per well in 96-well tissue culture
plates. hsiRNA, hydrophobically modified siRNA, was di-
luted in OptiMEM (Gibco, #31985-088) to a 2× stock con-
centration and 50 l of this solution was combined with 50
l of hepatocyte maintenance medium for a final volume of
100 l. Cells were incubated for 24 h at 37◦C and 5% CO2.
Cells were lysed and mRNA quantification was performed
using the QuantiGene 2.0 assay kit (Affymetrix).
Lipid-mediated delivery (HeLa cells)
Cells were plated in DMEM with 6% FBS at 10,000 cells
per well in 96-well tissue culture treated plates. siRNA
was diluted in OptiMEM, and mixed 1:1 with Lipo-
fectamine RNAiMAX Transfection Reagent (Invitrogen,
#13778150) (final transfection reagent concentration = 0.3
l/25 l/well). siRNA and transfection reagent was added
to cells resulting in 3% FBS final. Cells were incubated for
72 h at 37◦C and 5% CO2.
mRNA quantification from cells and tissue punches
mRNA was quantified using the QuantiGene 2.0 Assay
(Affymetrix, #QS0011). Cells were lysed in 250 l diluted
lysis mixture with proteinase K (Affymetrix, #13228) for 30
min at 55◦C. Probe sets were diluted as specified in the man-
ufacturer’s protocol. Cell lysates and diluted probe sets were
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Figure 1. Chemical composition and cellular efficacy of fully modified hsiRNAs. (A) Chemical structure, modification pattern, and molecular model of
partially (hsiRNA) and fully modified (FM-hsiRNA) hydrophobic siRNA. (B and C) Comparison of hsiRNA and FM-hsiRNA activity in vitro. HeLa
(B) or primary cytotrophoblasts (C) were incubated with hsiRNA or FM-hsiRNA at concentrations shown for 72h. mRNA levels were measured using
QuantiGene (Affymetrix) normalized to housekeeping gene (human PPIB for (B) and human YWHAZ for (C)), and presented as percent of untreated
control (n= 3, mean± SD). UNT––untreated cells. (D, E) RISC loading and cleavage comparison of unmodified, naked-siRNALET7, or FM-hsiRNALET7
(D) FM-hsiRNA LET7 shows an increase in loaded RISC as evident by single turnover target cleavage. (E) Multiple turnover cleavage rate (normalized to
loaded RISC) is similar between naked-siRNA, or FM-hsiRNA.
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added to the capture plate and amplification and lumines-
cent detection were carried out as specified in the manufac-
turer’s protocol.
Tissue punches (∼5 mg) were homogenized in 300 l
of Homogenizing Buffer (Affymetrix, #10642) with pro-
teinase K in a 96-well plate format on a QIAGEN TissueL-
yser II (Qiagen, #85300). Lysates and diluted probe sets
were added to the capture plate and signal was amplified
and detected according to themanufacturer’s protocol. This
method is described in detail in Coles et al. (23).
Luminescence was detected on either a Veritas Lumi-
nometer (Promega, #998-9100) or a Tecan M1000 (Tecan,
Morrisville, NC, USA). The specific mRNAs detected
are specified in each graph. Catalog numbers are as
follows: human HTT (Affymetrix, #SA-50339), mouse
HTT (Affymetrix, #SB-14150), human PPIB (Affymetrix,
#SA-10003), human sFLT1-i13 (Affymetrix, #SA-50459),
mouse sFlt1 (Affymetrix, #SB-50049). Data sets were nor-
malized to housekeeping genes specified in figure legends.
Catalog numbers are as follows: human PPIB (Affymetrix,
#SA-10003), mouse Ppib (Affymetrix, #SB-10002), hu-
man YWHAZ (Affymetrix, #SA-13271), mouse Flt1
(Affymetrix, #SB-14012).
PNA (peptide nucleic acid) based assay for detection of
hsiRNA in mouse tissues (24,25)
hsiRNA guide strand in tissues were quantified using PNA
hybridization assay. Tissues were lysed in MasterPure tis-
sue lysis Solution (EpiCentre, #MC85200) in the presence
of proteinase K (2 mg/ml) (Invitrogen, #25530-049) in Tis-
sueLyser II (Quiagen) (10mg tissue in 100 l lysis solution).
Sodium dodecyl sulphate (SDS) from lysate was precipi-
tated with KCl (3 M) and pelleted at 5000 g. hsiRNA in
cleared supernatant was hybridized to a Cy3-labeled PNA
fully complementary to guide strand (PNABio, Thousand
Oaks, CA, USA) and injected into HPLC DNAPac PA100
anion exchange column (Thermo Fisher, #043010) and Cy3
fluorescence was monitored and peaks integrated. Mobile
phase for HPLC was 50% water–50% acetonitrile, 25 mM
Tris–HCl (pH 8.5), 1 mM EDTA and salt gradient was 0–
800mMNaClO4. For the calibration curve known amounts
of hsiRNAsFLT1 duplexes were spiked into the tissue lysis so-
lution.
Animal experiments
Animal experiments were performed in accordance with an-
imal care ethics approval and guidelines of University of
Massachusetts Medical School Institutional Animal Care
and Use Committee (IACUC, protocol number A-2411).
Mice were 6–10 weeks of age at the time of experiments. All
animals were kept on 12-h light/dark cycle in pathogen-free
facility with food and water ad libitum. Before all studies
all animals were euthanized as follows: animals were deeply
anesthetized with 0.1% Avertin and transcardially perfused
with a 4%paraformaldehyde solution in phosphate buffered
saline, pH 7.2.
Injection of hsiRNA and FM-hsiRNA
For systemic administration of oligonucleotides C57BL/6
or FVB/NJ (both form Jackson Laboratory) mice were in-
jected either with phosphate buffered saline (PBS) or with
different amounts of hsiRNA, resuspended in PBS, through
the tail vein (IV) or SC. For in vivo tissue distribution
C57BL/6 were injected with 10 mg/kg of hsiRNAsFLT1 and
euthanized 24 h after injection. For in vivo efficacy FVB/NJ
mice were injected with 20 mg/kg using the same protocol.
Animals were euthanized 7 days after injection and tissues
were taken for microscopy, hsiRNA quantification (using
PNA hybridization assay), and for mRNA quantification
using QuantiGene 2.0 assay (23).
Imaging
C57BL/6 mice were injected intravenously (IV, via tail vein)
or subcutaneously (SC, interscapular, between shoulders)
with 10 mg/kg of Cy3-labeled hsiRNA (Cy3-hsiRNAsFLT1
or Cy3-FM-hsiRNAsFLT1). After 24 h mice were sacrificed
and liver, kidney, spleen, intestine, muscle (quadriceps),
pancreas, lung tissues, as well as fat, skin and tail from the
site of injection, were removed and fixed in 10% formalin
(Sigma, #HT501320) overnight at 4◦C. Fixed tissues were
embedded in paraffin, and sliced into 4 m sections that
were mounted on glass slides. Sections were deparaffinized
by incubating in Xylene twice for 8 min. Sections were rehy-
drated in serial ethanol solutions (100%, 95%, 80%dilutions
in water) for 4 min each, then washed twice for two minutes
with PBS. Washed slides were incubated with 0.25 g/ml
DAPI (Molecular Probes, #D3571) in PBS for 1 min then
washed twice for 2 min with PBS. Slides were mounted with
PermaFluormountingmedium (Thermo, #TA030FM) and
coverslips and dried overnight before imaging on a Leica
DM5500microscope fitted with aDFC365 FX fluorescence
camera.
Statistical analysis
Data were analyzed using GraphPad Prism 6 soft-
ware. IC50 curves were fitted using log(inhibitor) versus
response––variable slope (four parameters). For Figure 4A–
D, statistics were calculated using one-way ANOVA with
Tukey’s test for multiple comparisons, with significance cal-
culated relative to PBS control injected animals.
RESULTS
Full chemical stabilization enables efficient conjugate-
mediated siRNA efficacy in vitro
To compare the impact of partially or fully modified scaf-
folds on conjugate-mediated distribution and silencing in
vivo, we used asymmetric, cholesterol-modified siRNAs as a
model (Figure 1). The asymmetric design, termed hsiRNAs
(15-nucleotide passenger strand with a 3′-conjugate and 20-
nucleotide guide strand) lowers the melting temperature of
the double-strand region, to facilitate the dissociation of
the non-cleavable modified guide strand from the RNA-
Induced Silencing Complex (RISC) during loading. RISC
loading can happened through passenger strand cleavage
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(26) or dissociation. Full chemical modification of the pas-
senger strand blocks the cleavage pathway, leaving dissoci-
ation as the only functional alternative for RISC loading.
This makes the thermal melt (Tm) of the fully chemically
stabilized duplex one of the primary activity-limiting fac-
tors. The relative impact of asymmetric duplex configura-
tion on compound efficacy is sequence dependent. Supple-
mentary Figure S1A and B shows the activity of two siRNA
sequences in the context of either the conventional symmet-
ric (20-mer-20-mer) or asymmetric (15-mer-20-mer) duplex
configuration. For the siRNA targeting HTT there is no
difference between the two configurations, whereas for the
siRNA targeting sFLT1, reduction in duplex length sub-
stantially improves compound efficacy. The single-strand
region of the guide strand contains phosphorothioate link-
ages (27), providing additional stabilization and enhancing
cellular internalization (Ly. et al, prepared for publication).
This chemical scaffold has been extensively characterized
including mechanism of trafficking, clearance kinetics, and
systemic and local delivery (19,24,28–33).
Cholesterol conjugation to partially modified hsiRNAs
results in robust cellular uptake in vitro and potent lo-
cal silencing in vivo (28,30), but marginal systemic efficacy.
Thus, cholesterol-conjugated siRNAs provide a good start-
ing point to evaluate the impact of extensive chemical sta-
bilization on conjugate-mediated hsiRNA delivery.
Using a previously identified, partially modified hsiRNA
sequence targeting huntingtin (HTT) mRNA (30), we syn-
thesized and tested a panel of fully modified hsiRNAs
(FM-hsiRNAs) based on previously reported patterns (2,3).
Though several configurations were functional, an alter-
nating 2′-O-methyl, 2′–fluoro pattern, with a chemically
monophosphorylated, 2′-O-methyl-modified uridine (U) at
position 1, and a 2′-fluoro modified nucleotide at position
14 of the guide strand performed the best (Figure 1A, Sup-
plementary Figure S1C and Supplementary Table S1). An
alternating pattern with a 2′–fluoro in position 1 of the
guide strand reduced silencing activity (data not shown),
likely due to placement of 2′-O-methyl groups in positions
2 and 14, which negatively affects potency in the context of
heavily modified duplexes (34). The guide strand was also 5′
-chemically phosphorylated, as terminal 2′-O-methylatedU
is not a good a substrate for intracellular kinases as nat-
ural RNA. We also added two phosphorothioate linkages
to both 5′ and 3′ ends of the passenger and guide strands
to provide additional resistance to exonucleases. Figure 1A
shows the modification patterns and PyMol structure mod-
els of the conventionally modified hsiRNA and the most
active fully modified hsiRNA (FM-hsiRNA).
The FM-hsiRNA pattern supported similar or im-
proved silencing when applied to previously identified func-
tional siRNAs targeting HTT, PPIB, sFLT1, TIE2 (35),
PLK1 and SOD1 mRNAs (Figure 1B and C, Supplemen-
tal Figures S1 and S2 and data not shown). Moreover,
FM-hsiRNAs improved silencing in cultured primary neu-
rons and primary trophoblasts, adherent and suspension
cell types, respectively, both of which can be difficult to
transfect using conventional methods (36,37). The activ-
ity improvement provided by full chemical stabilization
was more pronounced in the non-adherent primary tro-
phoblasts where cholesterol mediated uptake is generally
slower (Figure 1C). When directly compared to an unmod-
ified, unconjugated siRNA, Chol-FM-hsiRNA showed sig-
nificantly enhanced efficacy following passive uptake (IC50
of 33.5 nM) while naked siRNA is inactive. However, both
compounds showed comparable potency (IC50 of 3.5 nM
for siRNA and 0.9 nM FM-hsiRNA) following lipid trans-
fection, further confirming that full modification is compat-
ible with RISC function in cells (Supplementary Figure S3).
Similarly, fully modified GalNAc-conjugated siRNAs were
more active in primary hepatocytes than partially modified
GalNAc-conjugated siRNAs (Supplementary Figure S4),
indicating that improvement in potency is not specific to the
nature of the conjugate or the cell type treated.
Fully chemically modified siRNAs are efficiently loaded into
RISC complex
The loading and cleavage rates of FM-hsiRNA were com-
pared to a completely non-modified Let-7 siRNA in a load-
ing and cleavage assay described earlier (38). The FM-
hsiRNA loaded almost three times more RISC complex
compared to the naked siRNA (Figure 1D), which is likely
a result of the enhanced stability of FM-hsiRNA. Once
the loaded RISC was under multiple turnover conditions
(37◦C), the in vitro cleavage rates of both the FM-hsiRNA
and the non-modified oligo were similar (after normalizing
to equal numbers of loaded RISC) (Figure 1E). Thus, full
modification does not interfere with the ability of the tested
oligonucleotide to be recognized by, and functionally load
into the RISC complex.
Comparison of partially and fully chemically modified siR-
NAs in conjugate-mediated systemic delivery
Both partially modified (e.g. all pyrimidines) and fully mod-
ified siRNAs have increased stability in vitro (from minutes
to days in 50% serum) over non-modified siRNAs (3,4). In
vivo, however, oligonucleotides are exposed to an aggres-
sive nuclease environment that cannot be adequately mim-
icked in vitro. Thus the stability of partially and fully mod-
ified siRNAs might be quite different from one another in
vivo. To compare the distribution of partially modified and
fully modified hsiRNAs in vivo, we administered 10 mg/kg
of Cy3-labeled Chol (cholesterol)-hsiRNA and Chol-FM-
hsiRNAby intravenous (IV) or subcutaneous (SC) injection
(Figure 2A and B). Twenty-four hours after injection, we
harvested tissues from mice and visualized the siRNA dis-
tribution by fluorescence microscopy. Injection of partially
modified Cy3-Chol-hsiRNA resulted in minimal levels of
fluorescence, observed only in liver and kidney. In contrast,
injection of Cy3-Chol-FM-hsiRNA resulted in intense ac-
cumulation of fluorescence in tissues throughout the body,
including liver, kidney, spleen, fat, and skin (Figure 2A and
B and data not shown).
To evaluate whether a significant enhancement in re-
tention upon full chemical stabilization is specific to the
cholesterol conjugate, we evaluated two other conjugates
with potential for tissue delivery: Docosahexaenoic acid
(DHA) (26), and GalNAc (39). The fully modified and par-
tially modified GalNAc and DHA conjugate compounds
were synthesized and their tissue distribution evaluated 24
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Figure 2. Systemically administered fully modified hsiRNA shows enhanced tissue distribution. Tissue distribution of Cy3-Chol-hsiRNA sFLT1 and Cy3-
Chol-FM-hsiRNA sFLT after 10 mg/kg intravenous (IV) tail vein injection (A) or 10 mg/kg subcutaneous (SC) injection (B). Tissue distribution of Cy3-
DHA-hsiRNA sFLT1 and Cy3-DHA-FM-hsiRNA sFLT after 10 mg/kg intravenous (IV) tail vein injection (C) or 10 mg/kg subcutaneous (SC) injection
(D). Tissue distribution of Cy3-GalNAc-hsiRNA sFLT1 and Cy3-GalNAc-FM-hsiRNA sFLT after 10 mg/kg intravenous (IV) tail vein injection (E) or 10
mg/kg subcutaneous (SC) injection (F). Cy3-hsiRNA (red), nuclei stained with DAPI (blue). For every conjugate the left panels are tiled tissue images
(scale bar = 1 mm) and the right panels are higher magnification tissue images (scale bar = 25 m). Image is representative.
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Figure 3. Systemic administration of fully modified hsiRNAs shows enhanced tissue accumulation. Guide strand tissue quantification by PNA
hybridization-based assay in tissues from Figure 2. Guide strand quantification of Cy3-Chol-hsiRNA sFLT1 and Cy3-Chol-FM-hsiRNAsFLT after 10
mg/kg intravenous (IV) tail vein injection (A) or 10 mg/kg subcutaneous (SC) injection (B). Guide strand quantification of Cy3-DHA-hsiRNA sFLT1 and
Cy3-DHA-FM-hsiRNA sFLT after 10mg/kg intravenous (IV) tail vein injection (C) or 10mg/kg subcutaneous (SC) injection (D). Guide strand quantifica-
tion of Cy3-GalNAc-hsiRNA sFLT1 and Cy3-GalNAc-FM-hsiRNA sFLT after 10 mg/kg intravenous (IV) tail vein injection (E) or 10 mg/kg subcutaneous
(SC) injection (F). Data presented as mean ± SD (n = 3 mice).
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h post IV and SC injection (Figure 2C–F). As with choles-
terol, we observed a substantial increase in compound tissue
accumulation with the FM-hsiRNA, independently of the
nature of the conjugate. It is important to notice that chang-
ing the conjugate resulted in a change in tissue distribution
profile, which could only be visualized in the context of fully
modified hsiRNA.
To insure that the qualitative robust difference observed
in fluorescence distribution between partially and fully
modified hsiRNAs is not an artifact of tissue process-
ing or presence of the fluorescent label, we used a PNA
hybridization-based assay (24,25) to evaluate the accumula-
tion of these compounds quantitatively. This method allows
for the detection of intact guide strands present in tissue
biopsies and is not dependent on the presence of the fluo-
rescent label. (Supplementary Figure S5). Figure 3 shows
the quantification data for the three different conjugates
(Cholesterol,DHA, andGalNAc) attached to fully and par-
tially modified hsiRNA scaffolds injected SC and IV. In all
cases, independently of the route of administration, or the
type of conjugate, over 100x tissue accumulation was ob-
served in the context of fully chemically modified siRNAs.
FM-hsiRNA guide strands accumulated to relatively high
levels, 20–200 ng/mg in liver, kidney, and spleen (Figure 2B
and C). Consistent with the imaging data, the tissue distri-
bution profile was effected by the type of conjugate used,
with cholesterol preferentially accumulating in liver (∼150
ng/mg), DHA in kidney (300–400 ng/mg) and GalNAc
in both liver and kidney (∼200 ng/mg). While cholesterol
and DHA show distribution to tissues beyond the liver and
kidney, such as the spleen, skin, and fat (data not shown),
GalNAc distribution was effectively exclusive to liver and
kidney (Figure 2E and F). Hence, full chemical stabiliza-
tion significantly enhances conjugate-mediated tissue accu-
mulation independent of the conjugate nature, or route of
administration, and is heavily reliant on the full chemical
modification of the siRNA.
Full chemical stabilization enables productive silencing in
vivo.
The poor accumulation and retention of partially modified
hsiRNAs is consistent with published studies showing that
systemic silencing by partially modified siRNA lipophilic
conjugates requires repetitive delivery with high doses (50–
80 mg/kg) (8). Consistently, when cholesterol-conjugated
partially modified hsiRNA was delivered systemically at 2
× 50 mg/kg dose levels we were unable to detect silencing,
even in the liver, a primary tissue where cholesterol modified
siRNAs distribute.
To confirm that significant FM-hsiRNA tissue accumu-
lation results in functional gene silencing, we evaluated si-
lencing efficiency in the liver and the kidney. For this ex-
periment, we selected the following targets: Ppib, a com-
monly used housekeeping gene expressed in all cell types,
Htt, a key target in Huntington’s disease, also expressed in
all cell types, and sFlt1 (soluble fms-like tyrosine kinase 1
or VEGFR1), which is primarily expressed in endothelial
cells and kidney proximal tubules epithelia, where Chol-
FM-hsiRNAs tend to accumulate (Figure 2A and B).
We, and others, have recently demonstrated that chem-
ical stabilization of the 5′ phosphate of the guide strand
increases in vivo efficacy of siRNA conjugates (17,19,40).
Thus for evaluation of targeted gene silencing in vivo, par-
tially and fully modified siRNA scaffolds were synthesized
with a 5′-(E)-vinyl phosphonate (VP). Animals were in-
jected with 20 mg/kg of fully or partially modified hsiR-
NAs. The level of targeted gene expression was evalu-
ated a week post injection using the QuantiGene 2.0 As-
say. We also injected a non-targeting control (NTC) com-
pound of the same chemical composition but not target-
ing the intended mRNA, and PBS as controls. For all three
genes tested, injection of controls resulted in no signifi-
cant changes in gene expression. In contrast, all three genes
were significantly silenced in liver after injection of a fully
chemically stabilized variant (Figure 4A-C). The same phe-
nomena was observed in kidney, where sFlt1 was signifi-
cantly downregulated by Chol-FM-hsiRNA (Figure 4D).
In both liver and kidney, partially modified hsiRNA did
not support efficient silencing. The degree of silencing varies
from target to target and is likely due to differences in cell
types and levels of targetmRNAexpression.While distribu-
tion and efficacy are significantly enhanced by full chemical
modification, injection of cholesterol, DHA and GalNAc-
conjugated, fully chemically modified, siRNAs were well
tolerated at the doses injected, with animals showing no ob-
servable adverse events or changes in blood chemistry (data
not shown).
This confirms that full chemical stabilization enables
both siRNA tissue accumulation and productive silencing.
DISCUSSION
Here we have compared partially and fully chemical modi-
fied siRNA scaffolds in conjugate mediated delivery in vitro
and in vivo. We have utilized a simple siRNA scaffold, uti-
lizing an alternating 2′-fluoro, 2′-O-methyl modification (3)
pattern in the context of an asymmetric siRNA. We have
shown that full chemical modification does not interfere
with RISC assembly and target cleavage in vitro and sup-
ports the activity of previously identified, functional siRNA
sequences (Figure 1 and Supplementary Table S1) in cell
culture. In fact, this chemical configuration supports effi-
cient RISC loading (similar or better than non-modified
RNA duplex) and target cleavage in vitro, allows productive
RISC assembly and function in cells and in vivo in animals.
Historically, extensive chemical modifications of siRNAs
were shown to negatively impact siRNA efficacy, resulting
only in a small fraction of pre-identified, functional, naked
siRNAs being successfully converted to modified scaffolds
(1,41–43). The two major contributors to modification-
related negative impact on silencing activity are modifica-
tions forcing the nucleic acid into a suboptimal geome-
try (both for loading and target cleavage) and/or making
the duplex too stable, interfering with guide strand load-
ing (26). Indeed, complete modification of the guide strand
with 2′-fluoro resulted in almost three fold drop in silenc-
ing efficacy in vitro (Supplemental Figure S1C). Both, 2′-
fluoro and 2′-O-methyl modifications favor the C3′-endo
ribose conformation, but 2′-fluoro modifications slightly
over-wind the duplex and 2′-O-methyl slightly under-wind
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Figure 4. Fully modified hsiRNAs are more efficacious than partially modified hsiRNAs following systemic administration. (A–C) Quantification of
target (Ppib, Htt, sFlt1, respectively)mRNA silencing in liver 7 days after SC administration of cholesterol-conjugated vhsiRNANTC, vFM-hsiRNANTC,
vhsiRNATarget, vFM-hsiRNATarget at 20 mg/kg. (D) Quantification of Ppib mRNA silencing in kidney 7 days after SC administration of cholesterol-
conjugated vhsiRNANTC, vFM-hsiRNANTC, *hsiRNA, *FM-hsiRNAsFlt1 at 20 mg/kg. FVBNj mice (n= 6 per group). mRNA levels were measured with
QuantiGene 2.0 (Affymetrix) assay.Htt, Ppib, and sFlt1mRNA levels normalized to housekeeping gene,Hprt. All data presented as percent of PBS treated
control. All error bars represent mean ± SD. *P < 0.05, ***P < 0.001; ****P < 0.0001 as calculated by one-way ANOVA with Tukey’s test for multiple
comparisons. v = 5′-vinyl phosphonate, NTC = non-targeting control.
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the RNA duplex. In addition, 2′-fluoro modification are
more hydrophobic and thus might contribute to enhance-
ment in cellular uptake and in vivo distribution (44). Al-
ternating these two types of modifications supports forma-
tion of an A-form helical structure, the geometry required
for guide strand-based positioning of the targeted mRNA
into the cleavage center of RISC (45). This is consistent with
the recently published crystal structure of a fully modified
guide strand showing ability to adopt a variety of confirma-
tions (46) Alternating 2′-fluoro and 2′-O-methyl modifica-
tions on both strands pairing 2′-fluoro on one strand with
2′-O-methyl on the other weakens the modification-induced
thermodynamic gain (2,3) and reduces the sequence re-
lated biases. The shorter (15-nucleotide) duplex region will
also help to promote release of the non-cleavable passen-
ger strand, alleviating a major thermodynamic limiting step
in RISC assembly with fully modified, FM-hsiRNAs (45).
Our findings suggest that RISC assembled with the asym-
metric fully modified-siRNA is as effective as RISC assem-
bled with non-modified siRNAs (Figure 1D and E). This
modification pattern can be applied to previously validated
siRNA sequences, as theHTT and PPIB sequences used in
this study were originally discovered using a partially modi-
fied scaffold. By switching the sequence to the fullymodified
pattern we effectively reduced the IC50 by almost 2.5× in
vitro. We are in the process of evaluating the exact impact
of these chemistries onRISC assembly and cleavage kinetics
using single molecule approaches (21).
Interestingly, the relative impact of full chemical modifi-
cation on in vitro efficacy was significantly less pronounced
than in vivo. Similar effects have been seen for 5′ phos-
phate stabilization where in vitro, 5′-vinyl phosphonate and
5′ phosphate hsiRNAs show similar efficacy, while in vivo
phosphate stabilization clearly enhances efficacy (19). It is
likely that in the harsh biological environment of systemic
delivery, chemical stabilization impact on efficacy is much
more pronounced than in vitro or upon local delivery.
Systemically administered FM-hsiRNAs accumulate in
tissues throughout the body including: liver, kidney, spleen,
fat, and skin. As expected, all oligonucleotides, including
lipophilic conjugated siRNAs (8,47) preferentially accumu-
lated in the liver where silencing of the target genes was ob-
served. Additionally, significant levels of compound accu-
mulated in the kidneys and spleen (Figures 2A-Dand 3), but
importantly the substantial differences observed between
the fully and partially modified siRNAswere not dependent
on the nature of the conjugates themselves but rather the
modification pattern of the siRNA.
The increase in tissue accumulation (50–250 ng/mg), was
observed with different conjugates, but it was predomi-
nantly the nature of conjugate that had an impact on tis-
sue distribution profile. This is consistent with a recently
published paper demonstrating that cholesterol modified
siRNAs can silence genes in muscle, although dose levels
necessary to achieve this effect were high (50mg/kg) (48).
DHA-conjugates accumulate to a higher extent in the kid-
neys, indicating that changing the nature of the conjugate
can be used as a strategy to alter tissue distribution. Inter-
estingly, withGalNAc–hsiRNAswe observed similar distri-
bution between kidneys and liver, specifically after SC ad-
ministration. This was surprising, as GalNAc internaliza-
tion is believed to be dependent on ASGPR (asialoglyco-
protein receptor) overexpressed in hepatocytes. It is possi-
ble that partial kidney delivery is due to the presence of the
single stranded phosphorothioated tail or the oversatura-
tion of the ASGPR receptors at the dose levels used in this
study (10 mg/kg).
With increased accumulation we observed an increase in
productive silencing. However, the level of silencing was not
directly proportional to the increase in siRNA tissue ac-
cumulation. It is well understood that for both antisense
oligonucleotides and siRNAs a significant fraction of inter-
nalized compound is trapped non-productively and differ-
ent cells accumulate oligonucleotides to different degrees.
This phenomenon is the subject of active investigation.
While the nature of the conjugate clearly effected tis-
sue accumulation, these effects can be observed only in
the context of a fully chemically modified scaffold. This
demonstrates that some previously discarded or dismissed
siRNA conjugates evaluated in the context of partially or
non-modified siRNAs might have served as viable delivery
strategies and may be worth re-testing in the context of a
fully modified pattern to show its true potential.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR online.
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